Rentschler sets up shop in the US with plans to grow CDMO services

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/LewisTsePuiLung)
(Image: Getty/LewisTsePuiLung)

Related tags CDMO Rentschler Biopharma Boston

A “strong client request” has prompted the CDMO Rentschler Biopharma to acquire its first US-based facility, which will provide various development and manufacturing services.

The 93,000 square foot site located near Boston in Milford, MA is the first outside of Germany for the contract development and manufacturing organization (CDMO).

Purchased from an affiliate of Shire plc, the site will offer services from clinic to market.

“The site will be leveraged by Rentschler Biopharma as an extension of our CDMO competence for the development and manufacturing of complex biopharmaceuticals,”​ a company spokesperson told us.

Under the terms of the agreement – financial details of which were not disclosed – the CDMO will continue to manufacture for Shire at the Milford site.

The spokesperson said the purchase follows “a strong client request,”​ and will enable the company to better meet customer needs.

“We plan to further grow the Milford site to a multi-product manufacturing facility and are currently evaluating and discussing new development and manufacturing options together with our clients,” ​they added.

The site's current employees, of which there are approximately 70, were all offered continued employment.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more